Ignite Creation Date:
2024-05-06 @ 6:15 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05605665
Status:
COMPLETED
Last Update Posted:
2024-07-09
First Post:
2022-10-29
Brief Title:
Low-dose Interleukin-2 and Rapamycin on sjögrens Syndrome
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
Therapeutic Effect of Low Dose IL-2 Combined With Rapamycin in on sjögrens Syndrome
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this paper is to analysis of therapeutic effect and immunological mechanism of low-dose IL-2 combined with rapamycin in the treatment of Sjogrens syndrome
Detailed Description:
A randomized open clinical trial was designed Patients will be randomly divided into three groupsincluding Ld-IL2 group rapamycin group Ld-IL2rapamycin group The improvement of clinical and laboratory indexes will be evaluated Changes of immune cell subsets and cytokines will be monitored
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None